Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AR | P10275 | 1/20 | 0.43 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | TP53 | P04637 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | P2RX7 | Q99572 | 4/20 | 0.38 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.37 |
| ▸ | PTPN7 | P35236 | 3/20 | 0.37 |
| ▸ | DUSP3 | P51452 | 3/20 | 0.37 |
| ▸ | SLC6A9 | P48067 | 3/20 | 0.37 |
| ▸ | KCNH2 | Q12809 | 3/20 | 0.37 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.36 |
| ▸ | SLC6A5 | Q9Y345 | 1/20 | 0.36 |
| ▸ | NR3C2 | P08235 | 1/20 | 0.36 |
| ▸ | GRIA2 | P42262 | 1/20 | 0.36 |
| ▸ | PCSK9 | Q8NBP7 | 1/20 | 0.35 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13504501 | 0.86 | CACNA1H (0.41) | — | |
| SCHEMBL2661623 | 0.78 | LMNA (0.42) | ARHDAC8LMNATP53MAPT | |
| SCHEMBL12780344 | 0.74 | HDAC8 (0.54) | ARHDAC8 | |
| SCHEMBL20363926 | 0.74 | HDAC8 (0.54) | ARHDAC8 | |
| SCHEMBL13504236 | 0.71 | RIPK1 (0.36) | MAPTP2RX7CYP3A4CYP2D6 | |
| SCHEMBL28782801 | 0.68 | RXRA (0.44) | ARLMNATP53MAPTP2RX7 | |
| SCHEMBL27364061 | 0.68 | ADORA2B (0.47) | ARLMNAMAPTSLC6A9KCNH2 | |
| SCHEMBL13463852 | 0.68 | KCNH2 (0.59) | ARP2RX7PTPN7DUSP3KCNH2 | |
| SCHEMBL2661784 | 0.68 | AR (0.41) | ARLMNATP53MAPTP2RX7 | |
| SCHEMBL28869336 | 0.66 | CYP11B1 (0.58) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100292143-A1 | PYRROLE-2-CARBOXAMIDE DERIVATIVES AS GLUCOKINASE ACTIVATORS, THEIR PROCESS AND PHARMACEUTICAL APPLICATION | ADVINUS THERAPEUTICS PRIVATE LIMITED (IN) | 2010-11-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100292143-A1 | PYRROLE-2-CARBOXAMIDE DERIVATIVES AS GLUCOKINASE ACTIVATORS, THEIR PROCESS AND PHARMACEUTICAL APPLICATION | GCK, PCK1, GCKR | AR 3938/4885HDAC8 856/4885LMNA 3790/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.